The Pharmaceutical Market: Saudi Arabia

Date: January 31, 2013
Pages: 108
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PBE3E3548A3EN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Saudi Arabia
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SAUDI ARABIA

Saudi Arabia' s transition to an increasingly privatised and comprehensive healthcare system will drive the demand for both patented and generic drugs . The country is investing heavily in healthcare infrastructure and we expect this will be borne out in double-digit growth forecasts across our three headline indicators.

Headline Expenditure Projections

Pharmaceuticals: SAR16.70bn (US$4.46bn) in 2011 to SAR18.95bn (US$5.06bn) in 2012; +13.5% in local currency and US dollar terms. Forecast broadly unchanged from Q3 12.

Healthcare: SAR78.63bn (US$21.00bn) in 2011 to SAR91.20bn (US$24.35bn) in 2012; +16.0% in local currency and US dollar terms. Forecast broadly unchanged from Q3 12.

Medical devices: SAR5.54bn (US$1.48bn) in 2011 to SAR6.53bn (US$1.74bn) in 2012; +17.8% in local currency and US dollar terms. Forecast unchanged from Q3 12.

Risk/Reward Rating: Saudi Arabia's composite score remained steady in Q4 12 at 55.6. This places the country to firth place out of the 30 markets in the region. Its score is propped up by the country's wealth and a sizeable population (exceeding 28mn in 2011). Furthermore, its forecast growth rate is high due to favourable public and private healthcare investments. The government is also in the process of creating more public-private health partnerships and encouraging private health insurance uptake, which should provide momentum for drug sales.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

    Saudi Arabia Pharmaceuticals And Healthcare SWOT
    Saudi Arabia Political SWOT
    Saudi Arabia Economic SWOT
    Saudi Arabia Business Environment SWOT

PHARMACEUTICAL RISK/REWARD RATINGS

    Table: Middle East And Africa Pharmaceutical Risk/Reward Ratings, Q113
    Rewards
    Risks

SAUDI ARABIA – MARKET SUMMARY

REGULATORY REGIME

    Regulatory Developments
    Regional Regulatory Developments
    Free Trade Agreements
    Intellectual Property Regime
    IP Deficiencies
    Counterfeit Drugs
    OTC Drug Market
    Pricing Regime
    Reimbursement Regime
    Pricing System Reform
    Tendering Procedures

INDUSTRY TRENDS AND DEVELOPMENTS

    Epidemiology
    Public Health Developments
    Healthcare Sector
    Healthcare Sector Funding
    Private Healthcare Sector
    Public And Private Healthcare Developments
    Healthcare Professionals
    Primary Healthcare Provision
    Secondary Healthcare Provision
    Health Insurance
    Health Insurance Developments
    Research and Development (R&D)
    Biotechnology
    Clinical Trials
    Medical Device Sector
    Medical Device Developments

INDUSTRY FORECAST SCENARIO

  Pharmaceutical Market Forecast
      Table: Pharmaceutical Sales Indicators, 2008-2016
  Healthcare Market Forecast
      Table: Healthcare Expenditure Indicators, 2008-2016
      Table: Government Healthcare Expenditure Indicators, 2008-2016
      Table: Private Healthcare Expenditure Indicators, 2008-2016
  Key Growth Factors – Macroeconomic
      Table: Saudi Arabia Long-Term Macroeconomic Forecasts
      Prescription Drug Market Forecast
      Table: Prescription Drug Sales Indicators, 2008-2016
  Patented Drug Market Forecast
      Table: Patented Drug Market Indicators, 2008-2016
      Generic Drug Market Forecast
      Table: Generic Drug Sales Indicators, 2008-2016
  OTC Medicine Market Forecast
      Table: OTC Medicine Sales Indicators, 2008-2016
  Pharmaceutical Trade Forecast
      Table: Exports and Imports Indicators, 2008-2016
      Medical Device Market Forecast
      Table: Medical Devices Sales Indicators, 2008-2016
  Other Healthcare Data Forecasts
  Key Risks To BMI Forecasts

COMPETITIVE LANDSCAPE

      Pharmaceutical Industry
      Foreign Industry
      Domestic Industry
      Regional Harmonisation
      Pharmaceutical Company Developments
      Pharmaceutical Distribution Sector
      Pharmaceutical Retail Sector
      Table: Pharmacies & Drug Stores, 2002-2009
      Table: Pharmacies & Drug Stores by Region, 2009

COMPANY PROFILES

  Domestic Company Profiles
      Saudi Pharmaceutical Industries And Medical Appliances Corp (SPIMACO)
      Saudi Arabian Japanese Pharmaceutical (SAJA)
      TABUK Pharmaceutical Manufacturing
      Jamjoom Pharma
  Multinational Company Profiles
      GlaxoSmithKline
      Novartis
      Merck & Co
      Pfizer
      Sanofi
      Hikma Pharmaceuticals Plc

DEMOGRAPHIC OUTLOOK

      Table: Population By Age Group, 1990-2020 (‘000)
      Table: Population By Age Group, 1990-2020 (% of total)
      Table: Key Population Ratios, 1990-2020
    Table: Rural/Urban Population Split, 1990-2020

GLOSSARY

BMI METHODOLOGY

    How We Generate Our Pharmaceutical Industry Forecasts
    Pharmaceuticals Risk/Reward Ratings Methodology
    Ratings Overview
    Table: Pharmaceutical Ris/Reward Indicators
    Weighting
    Table: Weighting Of Components
    Sources
Skip to top


Saudi Arabia Insurance Market Outlook to 2015 US$ 630.00 Mar, 2011 · 34 pages
Saudi Arabia Education Forecast to 2020 US$ 1,200.00 Jun, 2016 · 70 pages

Ask Your Question

The Pharmaceutical Market: Saudi Arabia
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: